Welcome to our dedicated page for BlossomHill Therapeutics news (Ticker: BLSM), a resource for investors and traders seeking the latest updates and insights on BlossomHill Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect BlossomHill Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of BlossomHill Therapeutics's position in the market.
BlossomHill Therapeutics (Nasdaq: BLSM), a clinical-stage biopharmaceutical company focused on small molecule cancer therapies, priced its upsized initial public offering of 9,375,000 common shares at $16.00 per share, for expected gross proceeds of $150.0 million before costs and any underwriter option exercise.
BlossomHill granted underwriters a 30-day option for up to 1,406,250 additional shares at the public price, less discounts and commissions. All shares are offered by the company. Trading on the Nasdaq Global Select Market is expected to begin on August 7, 2026 under the ticker BLSM, with closing expected on August 10, 2026, subject to customary conditions.
BlossomHill’s pipeline includes lead clinical candidates BH-30643 for EGFR-mutant NSCLC and BH-30236 for R/R AML or HR-MDS, plus preclinical KRAS program BH-501284.